Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5813403 | 0.80 | SMN1; SMN2 (0.47) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL4756373 | 0.79 | KMT2A (0.45) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL3866279 | 0.78 | BCHE (0.43) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL5350633 | 0.77 | PDPK1 (0.45) | CYP3A4 | |
| SCHEMBL5354727 | 0.76 | PDPK1 (0.44) | CYP3A4 | |
| SCHEMBL29751740 | 0.75 | CA12 (0.39) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL16879925 | 0.74 | METAP1 (0.40) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL4330519 | 0.74 | KMT2A (0.43) | KMT2AMEN1POLBSMN1; SMN2LMNA | |
| SCHEMBL7220728 | 0.74 | LMNA (0.39) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL4756423 | 0.74 | TLR7 (0.43) | NPC1RAB9AKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605943-A4 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7163947-B2 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| CN-1784231-A | 1-amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-06-07 | — | — | CN | disclosed |
| WO-2006028451-A1 | 1-AMINO 1-H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1605943-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | NPC1 2668/4885RAB9A 2024/4885KMT2A 2385/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | NPC1 2668/4885RAB9A 2024/4885KMT2A 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.